Myofascial Release Therapy Statistics in US 2026 | Key Facts

What Is Myofascial Release Therapy?

Myofascial release (MFR) therapy is a hands-on manual therapy technique that applies sustained, low-load pressure to the myofascial tissues — the complex system of muscle and connective tissue that wraps, connects, and supports virtually every structure in the human body — with the goal of releasing restrictions, reducing pain, and restoring normal movement and function. The technique was developed and formalised as a clinical discipline primarily through the work of physical therapist John F. Barnes in the 1960s and 1970s, and it has since grown into one of the most widely practised non-pharmacological approaches to chronic pain management in the United States and globally. Its defining characteristic is the application of gentle, sustained pressure — typically held for 90 seconds to several minutes at a single point — rather than the brisk, rhythmic strokes of classical massage. The theory is that prolonged pressure gradually softens and mobilises the fascia’s viscoelastic properties, releasing trigger points (hyperirritable nodules within taut bands of skeletal muscle) that cause both localised pain and characteristic referred pain patterns at distant body sites. As of 2026, MFR is practised by physical therapists, osteopathic physicians, massage therapists, chiropractors, and occupational therapists across thousands of clinical settings throughout the United States, from dedicated pain management clinics to hospital rehabilitation departments to sports medicine facilities.

The scale of clinical need driving demand for myofascial release therapy in the United States is substantial and growing. Approximately 9 million Americans are estimated to have myofascial pain syndrome (MPS) — the condition characterised by active trigger points and regional or referred pain that MFR directly targets — according to NCBI StatPearls (updated October 2025). More broadly, 14.4% of the general US population experiences chronic musculoskeletal pain (Expert Market Research / Research and Markets, 2025), and between 20% and 95% of patients presenting with musculoskeletal pain to general medicine or pain management clinics are estimated to be diagnosed with some form of myofascial pain, according to a landmark review published in the Best Practice & Research Clinical Rheumatology (2024). These figures position myofascial disorders as among the most prevalent and undertreated pain conditions in American healthcare, and MFR therapy as a clinically justified, increasingly evidence-backed approach to addressing them. The global MPS treatment market was valued at $1.11 billion in 2024 and is projected to reach $2.23 billion by 2032 at a CAGR of 8.49% (Data Bridge Market Research, 2025) — driven in significant part by rising demand for non-pharmacological therapies like MFR as patients and clinicians alike seek alternatives to long-term opioid use.

Interesting Facts About Myofascial Release Therapy in the US

Before the detailed statistics, here are the most striking and verified facts about myofascial release therapy and myofascial pain syndrome in the United States — the numbers and clinical evidence points that define the full landscape.

Source: NCBI StatPearls — Myofascial Pain (October 2025); Expert Market Research / Research and Markets Myofascial Pain Syndrome Epidemiology Forecast 2025–2034; Best Practice & Research Clinical Rheumatology (Lam et al., 2024, PubMed); BMC Musculoskeletal Disorders (physician survey); Data Bridge Market Research (2025); Verified Market Reports (2025); Future Market Insights (2026); Precedence Research (November 2025); PMC systematic review J Multidiscip Healthc (2024); ScienceDirect meta-analysis on fibromyalgia (279 patients); PubMed RCT chronic low back pain (2017)

Reading these facts together, what stands out most sharply is the extraordinary scale of need paired with a fragmented and often insufficient treatment response. Nearly one in seven Americans lives with chronic musculoskeletal pain — a figure that translates to tens of millions of people who are potential candidates for myofascial release therapy or related interventions. The statistic that 20% to 95% of patients presenting at pain clinics have myofascial involvement is not a narrow clinical finding — it describes the overwhelming majority of patients that pain specialists actually see every day. Against this backdrop, the fact that 54.3% of physicians who regularly treat MPS characterise the available treatment options as insufficient tells a powerful story about the size of the unmet need, and why demand for non-pharmacological interventions like MFR continues to grow even as the evidence base for some specific protocols remains inconsistent.

The fascia-centric model that underpins MFR has gained scientific credibility over the past decade as imaging technologies have improved the ability to visualise fascial restrictions and trigger points in real time. Ultrasound elastography can now locate myofascial trigger points non-invasively, giving clinicians a reproducible diagnostic tool where previously only manual palpation was available. This shift toward more objective diagnosis is gradually addressing one of MFR’s historical limitations — the subjective, hard-to-standardise nature of treatment delivery — and is helping to build a more rigorous evidence base that supports the integration of MFR into mainstream pain management protocols in US healthcare settings.

Myofascial Pain Syndrome Prevalence Statistics in the US

Source: NCBI StatPearls — Myofascial Pain Syndrome and Myofascial Pain (October 2025); Expert Market Research Myofascial Pain Syndrome Epidemiology Forecast (2025); Best Practice & Research Clinical Rheumatology — Lam et al. (PubMed 2024); BMC Musculoskeletal Disorders physician survey; PMC Journal of Multidisciplinary Healthcare (2024 — review of MFR therapy applications); Muscle & Nerve — Steen et al. (2025 update on MPS)

The prevalence range for myofascial pain syndrome is one of the widest in all of pain medicine — that span from 20% to 95% in pain clinic patients is not measurement error; it reflects genuine diagnostic uncertainty. MPS has historically been one of the most challenging conditions to diagnose reliably because it lacks a universally accepted diagnostic criterion, its primary finding (the trigger point) is detected primarily by manual palpation, and its symptoms — regional muscle pain, referred pain, reduced range of motion, muscle weakness — overlap significantly with other musculoskeletal diagnoses including fibromyalgia, neuropathic pain, and joint disorders. The result is a condition that is simultaneously everywhere and underrecognised: the physician who knows what to look for finds it in the majority of their musculoskeletal pain patients; the physician who does not may attribute the same symptoms to mechanical back pain, arthritis, or stress.

The 9 million Americans figure from StatPearls represents the diagnosed or clinically recognised pool — not the full epidemiological burden. When the 25%–54% of asymptomatic people with latent trigger points are considered, the total population with myofascial involvement at some level is vastly larger. Latent trigger points are clinically silent until activated by physical or psychological stress, overuse, poor posture, or injury — at which point they can become active trigger points generating spontaneous pain and referral patterns. For the millions of Americans working in sedentary office environments, dealing with stress-related muscle tension, or recovering from injury, latent trigger points represent a chronic background vulnerability to acute MPS episodes that MFR therapy is specifically designed to address prophylactically as well as therapeutically.

Myofascial Release Therapy — Clinical Evidence and Effectiveness Statistics

Source: ScienceDirect — systematic review and meta-analysis on MFR in fibromyalgia (279 patients); PMC Journal of Multidisciplinary Healthcare 2024 (comprehensive MFR applications review); PubMed — Effects of MFR in nonspecific CLBP RCT (2017); PMC — Effects of isolated MFR in CLBP systematic review (2023); PubMed — MFR physiological chains fibromyalgia RCT (2024); IJSAT 2024 study on fibromyalgia and chronic neck pain; PubMed — MFR effectiveness systematic review (Pubmed 2017); Best Practice Research Clin Rheumatology (Lam et al. 2024)

The evidence base for myofascial release therapy in 2026 is best described as promising but still developing — a characterisation that is accurate but requires some unpacking. The most robust evidence comes from fibromyalgia, where a systematic review and meta-analysis of six studies involving 279 patients found a large significant effect on pain immediately post-treatment and a moderate but sustained effect at six months. In the context of chronic pain research, where placebo effects are large and sustained treatment benefits are difficult to demonstrate, a moderate effect size at six months is clinically meaningful. The evidence for chronic low back pain, while supported by multiple RCTs and systematic reviews, shows more mixed results — partly because “chronic non-specific low back pain” is itself an extremely heterogeneous condition, and not all cases have a myofascial component of equal severity.

The honest scientific picture is that MFR works for some patients with some conditions, and the challenge for the field is developing better diagnostic tools to identify who those patients are and which treatment protocols produce the best outcomes. The acknowledgement in the BMC Musculoskeletal Disorders physician survey that 54.3% of treating physicians view available MPS treatments as insufficient is not a condemnation of MFR specifically — it reflects the broader reality that all current MPS treatments, including pharmacological ones, have significant limitations. The growing interest in ultrasound-guided intervention, combined with advances in fascial imaging and a more systematic approach to treatment protocol standardisation, is gradually building the evidence infrastructure that will allow MFR to be prescribed with the same specificity and confidence as other evidence-based physiotherapy techniques.

Myofascial Release Therapy Market and Industry Statistics 2026

Source: Data Bridge Market Research — MPS Treatment Market (January 2025); IMARC Group / BioSpace (February 2025); Verified Market Reports — Myofascial Release Tools (2025); Future Market Insights — Massage Therapy Services Market (February 2026); Precedence Research — Physical Therapy Market (November 2025); Research and Markets — Muscle Pain Treatment Market

The market data for myofascial release therapy and related services tells a consistent story: this is a segment of healthcare that is growing at a rate well above general healthcare inflation, driven by the convergence of several powerful structural forces. The ageing of the US population — with its associated increase in musculoskeletal disorders, arthritis, post-surgical rehabilitation needs, and chronic pain — is the most fundamental driver. A population that is living longer but increasingly burdened by pain and mobility limitations will inevitably seek out non-pharmacological interventions, particularly as the opioid crisis has dramatically changed both prescribing behaviour and patient preferences around pain management. Myofascial release therapy, along with related manual therapies, sits squarely in the beneficiary category of this shift.

The technological dimension of this market growth is equally significant. The $500 million self-myofascial release tools market — driven by foam rollers, massage balls, percussion devices, and IASTM tools — represents the democratisation of MFR techniques beyond the clinical setting. When Massage Envy, the largest massage franchise in the United States, introduced Aescape — a fully autonomous AI-driven robotic massage table — at select franchise locations in December 2025, it signalled that even the highest-volume, most mainstream segment of the massage therapy industry is moving toward technology-augmented delivery of the kinds of soft tissue techniques that include myofascial work. The convergence of evidence-based manual therapy protocols with precision technology and AI-driven personalisation is likely to reshape how MFR is delivered and documented in clinical settings over the next decade.

Myofascial Release Therapy — Conditions, Techniques and Applications Statistics

Source: Expert Market Research epidemiology forecast (2025); PMC Multidisciplinary Healthcare review (2024); PMC fibromyalgia treatment guidelines (2025); NCBI StatPearls MPS (April 2025); BMC Musculoskeletal Disorders physician survey; Muscle & Nerve review — Steen et al. (2025); IMARC Group MPS market report

The range of conditions that myofascial release therapy addresses in clinical practice is broader than its public image might suggest. Most people who have heard of MFR associate it primarily with back pain or sports injury recovery — and those are indeed among the most common applications. But the clinical literature increasingly documents MFR’s application in fibromyalgia, chronic pelvic pain, temporomandibular disorders, post-stroke rehabilitation, cancer survivor care, and even urological chronic pelvic pain syndromes. This breadth of application reflects a fundamental characteristic of the fascial system itself: because fascia is continuous throughout the body, creating functional chains that connect distant anatomical structures, restrictions or dysfunctions in the fascial system can generate pain and movement limitation far from the original site of injury or stress. A restriction in the thoracolumbar fascia can create referred symptoms in the legs; pelvic floor fascial tension can contribute to bladder symptoms; cervical fascial restrictions can generate headaches.

Posture and lifestyle factors are increasingly recognised as major contributors to the growing burden of myofascial pain in the United States — and the data from the Muscle & Nerve 2025 review is particularly pointed on this. Forward head posture, the characteristic spinal deformity associated with prolonged computer and smartphone use, places the cervical and shoulder muscles under sustained load that creates the exact conditions for trigger point formation. In a country where tens of millions of people spend eight or more hours daily in sedentary work postures, the structural conditions for widespread latent and active trigger point development are embedded in the everyday working environment. This is one reason the 25%–54% asymptomatic trigger point prevalence figure is so important: it means that a large fraction of the American workforce is one stressful period, one minor overuse injury, or one bad night’s sleep away from an acute MPS episode.

Myofascial Pain Syndrome Risk Factors and Demographics Statistics

Source: NCBI StatPearls — Myofascial Pain Syndrome (April 2025); NCBI StatPearls — Myofascial Pain (October 2025); Expert Market Research (2025); Muscle & Nerve — Steen et al. (2025 update on MPS clinical characteristics); BMC Musculoskeletal Disorders; PubMed RCT 2025 (Istanbul Medipol University)

The epidemiology of myofascial pain syndrome in the United States maps almost exactly onto the demographics of the modern American workforce, which is why the condition’s prevalence has not declined despite decades of advancement in pain medicine. Office workers spending extended hours in fixed postures are at elevated risk. Manual labourers with repetitive strain patterns are at elevated risk. Healthcare workers with physically demanding, high-stress environments are at elevated risk. Athletes and former athletes with accumulated micro-trauma histories are at elevated risk. And older Americans — whose age-related changes in muscle flexibility, circulation, and tissue repair capacity create ideal conditions for chronic trigger point maintenance — face the highest prevalence of all. These demographic overlaps with the large and growing American working population and ageing Baby Boomer cohort explain why the myofascial pain burden is not only large today but projected to grow.

The psychological dimension of MPS is one that deserves more clinical recognition than it typically receives. Stress is not merely an aggravating factor for myofascial pain — according to NCBI StatPearls, psychological stress is considered a major contributing factor to both trigger point activation and maintenance. The mechanism involves the sustained muscle tension patterns that accompany chronic psychological stress, which create the same conditions of prolonged low-level muscle overload that mechanical overuse produces. In a healthcare environment where mental health conditions including anxiety and depression are at historically high rates among American adults, the psychosomatic dimension of myofascial pain represents a significant treatment challenge that purely mechanical approaches to MFR may not fully address without concurrent psychological support.

Myofascial Release Therapy Treatment Approaches Statistics 2026

Source: NCBI StatPearls MPS (April 2025); BMC Musculoskeletal Disorders physician survey (332 physicians); Best Practice & Research Clinical Rheumatology — Lam et al. (PubMed 2024); IMARC Group MPS market report (February 2025); Expert Market Research (2025); Verified Market Reports MFR Tools (2025)

The treatment statistics from the BMC physician survey are as revealing as any clinical trial data when it comes to understanding the current state of MPS management in the United States. Manual therapy — including myofascial release — is prescribed by 81.1% of physicians treating MPS patients, making it the most commonly used physical modality. TENS is prescribed by 72.9% and acupuncture by 60.2%. Yet the same physicians rate the overall effectiveness of these treatments as only moderate (2.5 out of 6, where 1 is excellent), and 54.3% characterise the entire available treatment toolkit as insufficient. This is a healthcare gap of significant proportions: the treatments being prescribed are the best available, they are being used by the vast majority of knowledgeable clinicians, and yet the majority of those clinicians believe they are not good enough.

The emergence of ultrasound-guided techniques, PRP therapy, botulinum toxin injections, and neuromodulation approaches like TMS represents the next generation of MPS and myofascial pain treatment — interventions that address the condition with greater precision and potentially greater durability than traditional manual techniques alone. The inclusion of these modalities in market reports as significant growth drivers for 2025–2035 reflects a broader pharmaceutical and medical device industry recognition that myofascial pain represents a large, underserved patient population with documented unmet need and demonstrated willingness to seek treatment. For practitioners of myofascial release therapy, this evolution creates both competitive pressure and collaborative opportunity: the strongest evidence increasingly supports multimodal treatment approaches that combine manual MFR techniques with exercise prescription, postural correction, ergonomic intervention, and — where appropriate — pharmacological or interventional adjuncts.

Note: This article discusses myofascial release therapy statistics for informational and educational publishing purposes. It does not constitute medical advice. Individuals experiencing chronic pain or musculoskeletal conditions should consult a licensed healthcare professional for personalized diagnosis and treatment recommendations. If you are experiencing severe or persistent pain, please speak with your doctor.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE